{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:46:47Z","timestamp":1792802807864,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["110884"],"award-info":[{"award-number":["110884"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In elderly patients (pts) with aggressive B cell lymphoma (aNHL), curative treatment often cannot be administered because of comorbidities and tolerability. We analyzed the influence of age in pts &gt; 60 years receiving the R-CHOP-14 regimen within different prospective DSHNHL trials. Of the RICOVER-60 trial and CHOP-R-ESC trials, 1171 aNHL pts were included in this retrospective analysis of age-dependent event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). All patients received prophylactic G-CSF, and anti-infective prophylaxis with amphotericin B mouth wash and oral fluorchinolone was optional. In the CHOP-R-ESC trials, prophylaxis was augmented to include mandatory continuous orally administered aciclovir and a pneumocystis prophylaxis with cotrimoxazole as well as oral fluorchinolones during neutropenia. The patient population was separated into 4 age groups (61\u201365 years, 66\u201370 years, 71\u201375 years, and 76\u201380 years). The results from the RICOVER-60 trial were subsequently confirmed in the following CHOP-R-ESC trials by a multivariate analysis adjusted for IPI factors and gender. Significant differences (<jats:italic>p<\/jats:italic> &lt; 0.001) in EFS, PFS, and OS were seen between age groups (RICOVER-60). Hematotoxicity, infections, and TRM increased with age. TRM was significantly elevated in the age group 76\u201380 years. Therefore, this analysis shows that an age above 75 years defines an especially vulnerable patient population when being treated with chemoimmunotherapy for aNHL. Prophylactic anti-infective drugs are essential and clinically effective in reducing morbidity when treating elderly aNHL pts.<\/jats:p>","DOI":"10.1007\/s00277-020-04345-3","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T12:04:35Z","timestamp":1606392275000},"page":"1031-1038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma\u2014data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group)"],"prefix":"10.1007","volume":"100","author":[{"given":"Florian","family":"Zettl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Ziepert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Zeynalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"P\u00f6schel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hohloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald G.","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"issue":"11","key":"4345_CR1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, Lopez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial G (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12(11):1013\u20131022. https:\/\/doi.org\/10.1016\/S1470-2045(11)70235-2","journal-title":"Lancet Oncol"},{"issue":"4","key":"4345_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"issue":"2","key":"4345_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105\u2013116. https:\/\/doi.org\/10.1016\/s1470-2045(08)70002-0","journal-title":"Lancet Oncol"},{"issue":"24","key":"4345_CR4","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","volume":"116","author":"M Pfreundschuh","year":"2010","unstructured":"Pfreundschuh M (2010) How I treat elderly patients with diffuse large B-cell lymphoma. Blood 116(24):5103\u20135110. https:\/\/doi.org\/10.1182\/blood-2010-07-259333","journal-title":"Blood"},{"issue":"9","key":"4345_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","volume":"89","author":"T Hirakawa","year":"2010","unstructured":"Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K (2010) Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 89(9):897\u2013904. https:\/\/doi.org\/10.1007\/s00277-010-0956-7","journal-title":"Ann Hematol"},{"issue":"14","key":"4345_CR6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/jco.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR (2018) Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol 36(14):1443\u20131453. https:\/\/doi.org\/10.1200\/jco.2017.77.6211","journal-title":"J Clin Oncol"},{"issue":"9","key":"4345_CR7","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/annonc\/mdu208","volume":"25","author":"N Murawski","year":"2014","unstructured":"Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hanel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trumper L, Rixecker T, Zwick C (2014) Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol 25(9):1800\u20131806. https:\/\/doi.org\/10.1093\/annonc\/mdu208","journal-title":"Ann Oncol"},{"issue":"36","key":"4345_CR8","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1200\/jco.2013.54.6861","volume":"32","author":"M Pfreundschuh","year":"2014","unstructured":"Pfreundschuh M, Poeschel V, Zeynalova S, Hanel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N (2014) Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. J Clin Oncol 32(36):4127\u20134133. https:\/\/doi.org\/10.1200\/jco.2013.54.6861","journal-title":"J Clin Oncol"},{"issue":"3","key":"4345_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14860","volume":"179","author":"M Pfreundschuh","year":"2017","unstructured":"Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hanel M, Dierlamm J, Keller U, Dreyling M, Truemper L, Frickhofen N, Hunerliturkoglu AN, Schmitz N, Poschel V, Rixecker T, Berdel C, Rube C, Held G, Zwick C (2017) Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. Br J Haematol 179(3):410\u2013420. https:\/\/doi.org\/10.1111\/bjh.14860","journal-title":"Br J Haematol"},{"key":"4345_CR10","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","DOI":"10.1080\/01621459.1958.10501452"},{"key":"4345_CR11","first-page":"86327","volume":"17","author":"DDE DuBois","year":"1916","unstructured":"DuBois DDE (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:86327","journal-title":"Arch Intern Med"},{"issue":"6","key":"4345_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/annonc\/mdg249","volume":"14","author":"A Wunderlich","year":"2003","unstructured":"Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study G (2003) Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin\u2019s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 14(6):881\u2013893","journal-title":"Ann Oncol"},{"issue":"12","key":"4345_CR13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1634\/theoncologist.2014-0113","volume":"19","author":"PA Hamlin","year":"2014","unstructured":"Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S (2014) Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist 19(12):1249\u20131257. https:\/\/doi.org\/10.1634\/theoncologist.2014-0113","journal-title":"Oncologist"},{"issue":"7","key":"4345_CR14","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1158\/1078-0432.ccr-12-2837","volume":"19","author":"C Sarkozy","year":"2013","unstructured":"Sarkozy C, Coiffier B (2013) Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. Clin Cancer Res 19(7):1660\u20131669. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-2837","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4345_CR15","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3109\/10428194.2014.953142","volume":"56","author":"A Tucci","year":"2015","unstructured":"Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, Stelitano C, Fabbri A, Storti S, Fogazzi S, Mancuso S, Brugiatelli M, Fama A, Paesano P, Puccini B, Bottelli C, Dalceggio D, Bertagna F, Rossi G, Spina M (2015) Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma 56(4):921\u2013926. https:\/\/doi.org\/10.3109\/10428194.2014.953142","journal-title":"Leuk Lymphoma"},{"issue":"9880","key":"4345_CR16","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381(9880):1817\u20131826. https:\/\/doi.org\/10.1016\/S0140-6736(13)60313-X","journal-title":"Lancet"},{"issue":"9","key":"4345_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.6004\/jnccn.2016.0121","volume":"14","author":"AJ Olszewski","year":"2016","unstructured":"Olszewski AJ, Mantripragada KC, Castillo JJ (2016) Risk factors for early death after rituximab-based immunochemotherapy in older patients with diffuse large B-cell lymphoma. J Natl Compr Cancer Netw 14(9):1121\u20131129","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"4345_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, Andre M, Fournier M, Gaulard P, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte i (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12(5):460\u2013468. https:\/\/doi.org\/10.1016\/S1470-2045(11)70069-9","journal-title":"Lancet Oncol"},{"issue":"1","key":"4345_CR19","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/s2352-3026(16)30171-5","volume":"4","author":"F Peyrade","year":"2017","unstructured":"Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Ferme C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F (2017) Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol 4(1):e46\u2013e55. https:\/\/doi.org\/10.1016\/s2352-3026(16)30171-5","journal-title":"Lancet Haematol"},{"issue":"2","key":"4345_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/bjh.14232","volume":"175","author":"SI Park","year":"2016","unstructured":"Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, Muss HB, Shea TC (2016) A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol 175(2):281\u2013289. https:\/\/doi.org\/10.1111\/bjh.14232","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"4345_CR21","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1182\/blood-2019-122948","volume":"134","author":"F Zettl","year":"2019","unstructured":"Zettl F, Braulke F, Ziepert M, Viardot A, Kahl C, Prange-Krex G, Korfel A, Dreyling MH, Illmer T, Birkmann J, Wedding U, Reichert D, Md W, Hartmann F, Hurtz H-J, Schmitz N, Witzens-Harig M, Klapper W, Rosenwald A, Poeschel V, Loeffler M, Wulf G, Altmann B, Truemper L (2019) Rituximab and bendamustine for first-line treatment of frail or elderly patients with aggressive B-cell lymphoma: final results of the prospective phase-II Brenda trial of GLA (German Lymphoma Alliance). Blood 134(Supplement_1):4073","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04345-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-020-04345-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04345-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T09:40:18Z","timestamp":1615801218000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-020-04345-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4345"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04345-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]},"assertion":[{"value":"14 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Bertram Glass Roche AG research funding and honoraria, Gerhard Held Roche and Amgen research funding, Viola Poeschel Roche and Amgen travel grants, and Florian Zettl Roche travel grants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}